Drugs

, Volume 66, Issue 3, pp 321–340

Mitomycin

Clinical Applications in Ophthalmic Practice

Authors

  • Lekha M. Abraham
    • Department of Ophthalmology and Visual SciencesRoyal Adelaide Hospital, University of Adelaide
  • Dinesh Selva
    • Department of Ophthalmology and Visual SciencesRoyal Adelaide Hospital, University of Adelaide
    • Departments of Medicine and SurgeryUniversity of Adelaide
  • Robert Casson
    • Department of Ophthalmology and Visual SciencesRoyal Adelaide Hospital, University of Adelaide
    • Department of Ophthalmology and Visual SciencesRoyal Adelaide Hospital, University of Adelaide
Review Article

DOI: 10.2165/00003495-200666030-00005

Cite this article as:
Abraham, L.M., Selva, D., Casson, R. et al. Drugs (2006) 66: 321. doi:10.2165/00003495-200666030-00005

Abstract

Mitomycin (mitomycin C; MMC) is an antibiotic isolated from Streptomyces caespitosus. The drug is a bioreductive alkylating agent that undergoes metabolic reductive activation, and has various oxygen tension-dependent cytotoxic effects on cells, including the cross-linking of DNA. It is widely used systemically for the treatment of malignancies, and has gained popularity as topical adjunctive therapy in ocular and adnexal surgery over the past 2 decades.

In ophthalmic medicine, it is principally used to inhibit the wound healing response and reduce scarring of surgically fashioned ostia. Hence, it has been used as adjunctive therapy in various ocular surgeries, such as glaucoma filtering surgeries, dacryocystorhinostomy, corneal refractive surgery and surgeries for ocular cicatrisation. In addition, it has been used as an adjunct in the surgical management of pterygia, ocular surface squamous neoplasia, primary acquired melanosis with atypia and conjunctival melanoma. In many of these surgeries and ophthalmic pathologies, MMC showed a significant beneficial effect.

Copyright information

© Adis Data Information BV 2006